Part 2: Practical Considerations For Venetoclax in AML

Author(s):

Expert continues discussion on important considerations for the optimal use if venetoclax in patients with AML, such as CYP3A4 and p-glycoprotein drug interactions.

EP: 1.Role of First Generation FLT3 Inhibitors in AML

EP: 2.Role of Second Generation FLT3 Inhibitors in AML

EP: 3.Part 1: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML

EP: 4.Part 2: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML

EP: 5.Role of Venetoclax in Treatment of AML

EP: 6.Part 1: Practical Considerations For Venetoclax in AML

Now Viewing

Part 2: Practical Considerations For Venetoclax in AML

EP: 1.Role of First Generation FLT3 Inhibitors in AML

EP: 2.Role of Second Generation FLT3 Inhibitors in AML

EP: 3.Part 1: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML

EP: 4.Part 2: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML

EP: 5.Role of Venetoclax in Treatment of AML

EP: 6.Part 1: Practical Considerations For Venetoclax in AML

EP: 7.Part 2: Practical Considerations For Venetoclax in AML

EP: 8.5-Year Follow-Up Data For CPX-351 in AML

EP: 9.CPX-351 in Clinical Practice For AML